SCHEDULE OF WARRANTS OUTSTANDING (Details) - $ / shares |
12 Months Ended | |
---|---|---|
Dec. 31, 2022 |
Dec. 31, 2021 |
|
Stock Warrants | ||
Number of warrants, outstanding, beginning balance | 24,122 | 370,000 |
Weighted average exercise price, outstanding, beginning balance | $ 3.13 | $ 8.75 |
Number of warrants, issued | ||
Weighted average exercise price, issued | ||
Number of warrants, exercised | (345,878) | |
Weighted average exercise price, exercised | $ 4.07 | |
Number of warrants, outstanding, ending balance | 24,122 | 24,122 |
Weighted average exercise price, outstanding, ending balance | $ 3.13 | $ 3.13 |
Number of warrants, exercisable, ending balance | 24,122 | |
Weighted average exercise price, exercisable, ending balance | $ 3.13 |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Share based payment award non options exercisable number. No definition available.
|
X | ||||||||||
- Definition The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the warrants. No definition available.
|
X | ||||||||||
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the warrants. No definition available.
|
X | ||||||||||
- Definition Weighted average price at which option holders acquired shares when converting their stock warrants into shares. No definition available.
|
X | ||||||||||
- Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants. No definition available.
|
X | ||||||||||
- Definition Number of non-option equity instruments exercised by participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|